Floatz logo

Kln-1010

Vascular Disorder

Kelonia Therapeutics, Inc.gene_therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Vascular Disorder cohort.

Asset / SponsorPhaseRating
Triticum Aestivum
Coordinación de Investigación en Salud, Mexico
Phase 3BB
Calcined Magnesia
Coordinación de Investigación en Salud, Mexico
Phase 3BB
Empagliflozin
VA Office of Research and Development
Phase 2CCC

Same molecule, other indications

Kln-1010 is also rated in:

neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
vascular hemostatic diseaseDormant
CC
Indicative ·
43 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →